2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Deubiquitinase
  5. USP2 Isoform

USP2

USP2 is a ubiquitin-specific deubiquitinase that regulates protein ubiquitination, protein stability, and cellular proteostasis[1][2]. Mechanistically, USP2 connects ubiquitin-proteasome signaling with cell survival, cell cycle control, circadian rhythm, metabolism, inflammation, antiviral response, and metastasis through substrates including Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, and TGFBR complexes[1]. In disease models, USP2 elevation has been reported in glioma, testicular cancer, breast cancer, prostate cancer, inflammatory diseases, and hepatocellular carcinoma models[1][3]. Compared with related isoforms, USP2a and USP2b show distinct biological roles: USP2a attenuates diabetes in adipose tissue macrophages, whereas USP2b aggravates type 2 diabetes and metabolic dysfunction-associated steatotic liver disease in hepatocytes[4]. In hepatocellular carcinoma, USP2 stabilizes PPARγ, promotes fatty-acid biosynthesis and oleic acid production, and supports M2 macrophage polarization[5]. For experimental applications, ML364 showed anticancer responses against HCC patient-derived organoids, while current USP2 inhibitors remain unapproved clinically and require improved specificity[1][5].

USP2 Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-162312
    LLK203
    		Inhibitor 98.58%
    LLK203 is a potent USP2/USP8 dual-target inhibitor with IC50s of 0.89 μM and 0.52 μM, respectively. LLK203 leads a degradation of ERα and induces apoptosis of breast cancer MCF-7 cells. LLK203 demonstrates antitumor activities against the 4T1 tumor mice model.
  • HY-RS15530
    USP2 Human Pre-designed siRNA Set A
    		Inhibitor

    USP2 Human Pre-designed siRNA Set A contains three designed siRNAs for USP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-179630
    MS102
    		Inhibitor
    MS102 is an orally active ubiquitin specific peptidase 2 (USP2) inhibitor with an IC50 of 5.46 μM. MS102 has viable antiviral activity against ACE2-dependent coronaviruses. MS102 significantly reduces V-domain Ig suppressor of T cell activation (VISTA) protein abundance in vitro and in vivo. MS102 can be used for the study of SARS-CoV-2. MS102 can be used in combination with anti-PD-1 immunotherapy to enhance the anti-tumor immune response.